PCRX

Handel nachbörslich: 17.28

Pacira Biosciences Inc (PCRX)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

24-Stunden-Volumen:

Relative Volume:

Marktkapitalisierung:

Nettoeinkommen (Verlust:

Netto-Cashflow:

1W Leistung:

1M Leistung:

6M Leistung:

1J Leistung:

1-Tages-Spanne:

1-Wochen-Bereich:

52-Wochen-Spanne:

Pacira Biosciences Inc Stock (PCRX) Company Profile

Pacira Biosciences Inc

Healthcare (1182)

813-553-6680

5401 WEST KENNEDY BOULEVARD, TAMPA, NJ

Nächster Verdiensttermin

Neueste SEC-Einreichungen

PCRX's Discussions on Twitter

Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2023-12-20	Eingeleitet	Raymond James	Outperform
2023-08-03	Hochstufung	TD Cowen	Market Perform → Outperform
2023-01-31	Fortgesetzt	Wedbush	Outperform
2022-10-21	Fortgesetzt	Jefferies	Buy
2022-01-03	Fortgesetzt	JP Morgan	Overweight
2021-07-26	Hochstufung	JP Morgan	Neutral → Overweight
2021-04-21	Fortgesetzt	JP Morgan	Neutral
2021-04-09	Eingeleitet	Berenberg	Buy
2021-04-07	Fortgesetzt	RBC Capital Mkts	Outperform
2021-02-11	Herabstufung	Northland Capital	Outperform → Market Perform
2021-01-21	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2020-09-21	Hochstufung	Northland Capital	Market Perform → Outperform
2020-07-06	Bestätigt	Needham	Buy
2020-05-27	Eingeleitet	Guggenheim	Neutral
2020-04-07	Eingeleitet	Northland Capital	Outperform
2020-03-20	Hochstufung	SVB Leerink	Mkt Perform → Outperform
2020-02-24	Bestätigt	H.C. Wainwright	Buy
2020-01-24	Eingeleitet	SunTrust	Buy
2020-01-23	Eingeleitet	SunTrust	Buy
2019-11-06	Eingeleitet	BTIG Research	Buy
2019-06-11	Eingeleitet	Barclays	Overweight
2019-05-06	Hochstufung	Mizuho	Underperform → Neutral
2019-05-02	Hochstufung	Stifel	Sell → Hold
2019-02-01	Herabstufung	Mizuho	Neutral → Underperform
2018-08-06	Herabstufung	BofA/Merrill	Buy → Neutral
2018-04-09	Bestätigt	H.C. Wainwright	Buy
2018-03-21	Bestätigt	Mizuho	Neutral
2018-02-16	Herabstufung	Needham	Buy → Hold
2018-01-19	Eingeleitet	Seaport Global Securities	Buy
2018-01-04	Bestätigt	Canaccord Genuity	Buy
2018-01-03	Eingeleitet	Leerink Partners	Mkt Perform

Alle ansehen

Pacira Biosciences Inc Aktie (PCRX) Neueste Nachrichten

Finanzdaten der Pacira Biosciences Inc-Aktie (PCRX)

Pacira Biosciences Inc (PCRX)

Pacira Biosciences Inc Stock (PCRX) Company Profile

Pacira Biosciences Inc Stock (PCRX) Upgrades & Downgrades

Pacira Biosciences Inc Aktie (PCRX) Neueste Nachrichten

Insights into Pacira BioSciences's Upcoming Earnings - Benzinga

Pacira BioSciences Inc (PCRX) Q3 2024: Everything You Need To Kn - GuruFocus.com

Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat

Trading (PCRX) With Integrated Risk Controls - Stock Traders Daily

Rice Hall James & Associates LLC Sells 730,288 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat

Pacira BioSciences (PCRX) Set to Announce Quarterly Earnings on Wednesday - MarketBeat

Allspring Global Investments Holdings LLC Buys 93,497 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat

Pacira to Report Third Quarter 2024 Financial Results on Wednesday November 6, 2024 - GlobeNewswire

Assenagon Asset Management S.A. Buys 419,656 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat

Shawn Cross appointed as chief financial officer for Pacira Biosciences - Pharmafile

When the Price of (PCRX) Talks, People Listen - Stock Traders Daily

Pacira BioSciences appoints Shawn Cross as CFO By Investing.com - Investing.com Australia

Pacira BioSciences appoints Shawn Cross as CFO - Investing.com

Are Options Traders Betting on a Big Move in Pacira BioSciences (PCRX) Stock? - MSN

Pacira BioSciences Appoints Shawn Cross As Chief Financial Officer - citybiz

Pacira BioSciences Names Shawn Cross Chief Financial Officer - MarketWatch

Pacira BioSciences Appoints Shawn Cross as Chief Financial Officer - GlobeNewswire

Q1 EPS Estimate for Pacira BioSciences Reduced by Analyst - MarketBeat

Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Purchased by Wedge Capital Management L L P NC - MarketBeat

Pacira BioSciences Inc (PCRX) may enjoy gains as insiders got busy in the recent days - Knox Daily

Was Pacira BioSciences Inc (PCRX)’s session last reading good? - US Post News

(PCRX) Trading Advice - Stock Traders Daily

A company insider recently sold 500 shares of Pacira BioSciences Inc [PCRX]. Should You Sale? - Knox Daily

What is the investor’s view on Pacira BioSciences Inc (PCRX)? - US Post News

Analysts Set Pacira BioSciences, Inc. (NASDAQ:PCRX) PT at $24.20 - MarketBeat

Analytical Overview: Pacira BioSciences Inc (PCRX)’s Ratios Tell a Financial Story - The Dwinnex

Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Sold by Bank of Montreal Can - MarketBeat

PCRX stock rated a Sell by Truist - Knox Daily

A Look at Pacira BioSciences Inc (PCRX) Shares in the Recent Past Indicates Growth - SETE News

Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - The Manila Times

Sei Investments Co. Sells 279,140 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat

Are Pacira BioSciences, Inc.'s (NASDAQ:PCRX) Mixed Financials Driving The Negative Sentiment? - Simply Wall St

The three-year loss for Pacira BioSciences (NASDAQ:PCRX) shareholders likely driven by its shrinking earnings - Yahoo Finance

Pacira BioSciences (NASDAQ:PCRX) Price Target Raised to $15.00 at Royal Bank of Canada - MarketBeat

Pacira's Exparel Receives Permanent New Product-Specific J-Code - Zacks Investment Research

Pacira wins Exparel Medicare J-code (NASDAQ:PCRX) - Seeking Alpha

Pacira BioSciences Announces New Product-Specific J-Code for EXPAREL Effective January 1, 2025 - GlobeNewswire

CMS grants new J-code for Pacira's non-opioid pain therapy - Investing.com

Pacira BioSciences Inc (PCRX)’s stock rises to 15.30 per share - US Post News

Pacira BioSciences' SWOT analysis: stock faces patent challenges amid growth initiatives - Investing.com India

Pacira BioSciences, Inc. (NASDAQ:PCRX) Shares Acquired by Dimensional Fund Advisors LP - MarketBeat

Pacira Pharmaceuticals Announces CFO Transition and Interim Replacement - TipRanks

Marshall Wace LLP Acquires 159,791 Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat

Pacira to present new gene therapy data for knee osteoarthritis By Investing.com - Investing.com Australia

Doma Perpetual Capital Management LLC Has $28.63 Million Stock Position in Pacira BioSciences, Inc. (NASDAQ:PCRX) - MarketBeat

Pacira Announces the Presentation of 104-Week Safety and - GlobeNewswire

Pacira to present new gene therapy data for knee osteoarthritis - Investing.com

Pacira BioSciences (NASDAQ:PCRX) Shares Gap Up After Analyst Upgrade - MarketBeat

DOMA Perpetual Sends Letter to Board of Directors of Pacira Biosciences to Immediately Accelerate and Increase its Share Buyback Program to Enhance Return to Shareholders - PR Newswire

Pacira BioSciences (NASDAQ:PCRX) Price Target Increased to $18.00 by Analysts at Jefferies Financial Group - MarketBeat

Expert Ratings For Pacira BioSciences - Benzinga

Finanzdaten der Pacira Biosciences Inc-Aktie (PCRX)

Umsatz

Nettogewinn

Free Cashflow

ENV

Ähnlich wie PCRX